90,756 Shares in Hims & Hers Health, Inc. (NYSE:HIMS) Purchased by Tybourne Capital Management HK Ltd.

Tybourne Capital Management HK Ltd. bought a new stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 90,756 shares of the company's stock, valued at approximately $1,672,000. Hims & Hers Health comprises about 0.5% of Tybourne Capital Management HK Ltd.'s holdings, making the stock its 26th largest position.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. FORA Capital LLC acquired a new stake in Hims & Hers Health during the third quarter worth about $1,411,000. Blueshift Asset Management LLC grew its stake in shares of Hims & Hers Health by 834.8% during the 3rd quarter. Blueshift Asset Management LLC now owns 245,013 shares of the company's stock worth $4,513,000 after purchasing an additional 218,804 shares during the period. Bridgewater Associates LP increased its holdings in shares of Hims & Hers Health by 63.8% during the 3rd quarter. Bridgewater Associates LP now owns 301,072 shares of the company's stock valued at $5,546,000 after purchasing an additional 117,251 shares in the last quarter. DRW Securities LLC acquired a new position in shares of Hims & Hers Health in the 3rd quarter valued at $2,017,000. Finally, Alpha DNA Investment Management LLC purchased a new stake in Hims & Hers Health during the third quarter worth $552,000. Institutional investors and hedge funds own 63.52% of the company's stock.

Hims & Hers Health Price Performance

Hims & Hers Health stock traded down $0.34 during trading on Thursday, reaching $30.34. 24,738,795 shares of the company were exchanged, compared to its average volume of 9,806,751. The stock's 50 day simple moving average is $21.42 and its two-hundred day simple moving average is $19.65. The company has a market capitalization of $6.63 billion, a P/E ratio of 68.95 and a beta of 1.06. Hims & Hers Health, Inc. has a 52-week low of $8.09 and a 52-week high of $35.02.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $401.56 million for the quarter, compared to analysts' expectations of $382.20 million. During the same quarter in the previous year, the company posted ($0.04) EPS. The company's revenue was up 77.1% compared to the same quarter last year. As a group, equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on HIMS. Needham & Company LLC started coverage on shares of Hims & Hers Health in a research report on Thursday, August 22nd. They issued a "buy" rating and a $24.00 price objective for the company. TD Cowen reiterated a "buy" rating and set a $28.00 price target on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Bank of America downgraded Hims & Hers Health from a "buy" rating to an "underperform" rating and reduced their target price for the stock from $32.00 to $18.00 in a research note on Thursday, November 14th. Imperial Capital cut shares of Hims & Hers Health from an "outperform" rating to an "in-line" rating in a research note on Friday, August 9th. Finally, Deutsche Bank Aktiengesellschaft upped their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a "hold" rating in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $20.71.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 2,345 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $14.65, for a total transaction of $34,354.25. Following the completion of the transaction, the insider now owns 159,796 shares of the company's stock, valued at $2,341,011.40. This trade represents a 1.45 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Andrew Dudum sold 188,888 shares of Hims & Hers Health stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the sale, the chief executive officer now owns 33,502 shares of the company's stock, valued at approximately $487,789.12. This represents a 84.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,153,519 shares of company stock worth $24,486,721 in the last 90 days. Insiders own 17.71% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.